Icahn School of Medicine at Mount Sinai, USA.
Neuroradiol J. 2022 Jun;35(3):313-318. doi: 10.1177/19714009211041520. Epub 2021 Sep 2.
The delivery of flow-diverting stents (FDS) necessitates a degree of catheter support beyond that required for endovascular coiling. The TracStar Large Distal Platform (LDP) is a novel 0.088″ platform intended for navigation into the intracranial internal carotid artery (ICA). We present an early institutional experience using the TracStar LDP in 44 cases of endovascular aneurysm embolization using FDS.
Inclusion criteria for this single-center retrospective review encompassed all patients >18 years of age who were treated for intracranial aneurysms. Procedural success was defined as successful stent deployment using the TracStar LDP. Other outcomes included periprocedural complications, use of an intermediate catheter, length of stay, and discharge disposition.
The TracStar LDP was utilized in 44 consecutive FDS cases in 42 patients. Cavernous segment aneurysms constituted the majority of cases (12/42; 28.6%), followed by posterior communicating artery (8/42; 19.0%) and supraclinoid aneurysms (8/42; 19.0%). Successful FDS deployment was achieved in 43/44 cases. The LDP achieved stable positioning within the ascending cavernous ICA in 63.6% of cases. A biaxial system was utilized in 54.5% of cases. There was one complication potentially related to use of the TracStar LDP, which was an asymptomatic ICA vessel dissection managed conservatively.
The TracStar LDP is safe and effective during use in the endovascular treatment of intracranial aneurysms with a FDS. Access to the ascending portion of the cavernous ICA was regularly achieved, and the platform allowed for both biaxial and triaxial configurations.
血流导向装置（FDS）的输送需要比血管内线圈植入更高程度的导管支持。TracStar 大远端平台（LDP）是一种新型的 0.088"平台，旨在进入颅内颈内动脉（ICA）。我们介绍了使用 TracStar LDP 在 44 例使用 FDS 的血管内动脉瘤栓塞中的早期机构经验。
本单中心回顾性研究的纳入标准包括所有年龄>18 岁的颅内动脉瘤患者。程序成功定义为使用 TracStar LDP 成功部署支架。其他结果包括围手术期并发症、使用中间导管、住院时间和出院处置。
TracStar LDP 在 42 例 44 例连续 FDS 病例中得到应用。海绵窦段动脉瘤构成大多数病例（12/42；28.6%），其次是后交通动脉（8/42；19.0%）和前床突动脉瘤（8/42；19.0%）。43/44 例 FDS 成功部署。LDP 在 63.6%的病例中稳定定位在ICA 升段。54.5%的病例使用双轴系统。有一例与使用 TracStar LDP 相关的并发症，为无症状的 ICA 血管夹层，保守治疗。
在使用 FDS 治疗颅内动脉瘤的血管内治疗中，TracStar LDP 是安全有效的。经常能够进入海绵窦 ICA 的升段，并且该平台允许双轴和三轴配置。
